Loading...

FITC anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_FITC_021009.jpg
Human peripheral blood lymphocytes stained with OKT4 FITC
  • OKT4_FITC_021009.jpg
    Human peripheral blood lymphocytes stained with OKT4 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
317407 25 tests 18€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317408 100 tests 40€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Varkey R, et al. 2019. PLoS One. 14:e0211236. PubMed
  2. Yang M, et al. 2019. Cell Physiol Biochem. 52:1178. PubMed
  3. Sasaki E, et al. 2018. J Immunotoxicol. 15:53. PubMed
  4. Gan X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200879119. PubMed
  5. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  6. Rosain J, et al. 2023. Cell. 186:621. PubMed
  7. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  8. Riaz T, et al. 2016. Mol Cell Proteomics. 15: 1007 - 1016. PubMed
  9. Trzupek D, et al. 2022. Wellcome Open Res. 6:149. PubMed
  10. Andonian BJ, et al. 2022. Sci Rep. 12:7450. PubMed
  11. Kieffer T, et al. 2017. J Reprod Immunol. 10.1016/j.jri.2016.11.004. PubMed
  12. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  13. Zhao Y, et al. 2021. Front Immunol. 12:665442. PubMed
  14. Rodriguez-García A, et al. 2020. Mol Ther. 28:548. PubMed
  15. Enghard P, et al. 2014. Ann Rheum Dis. 73:277. PubMed
  16. Hixon JA, et al. 2020. Leukemia. 34:35. PubMed
  17. Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
  18. Zhou Y, et al. 2017. Front Cell Infect Microbiol. 7:457. PubMed
  19. Gorczynski RM, et al. 2017. Immunology. 150:418. PubMed
  20. Meng S, et al. 2018. Mol Med Rep. 18:4247. PubMed
  21. Buchan SL et al. 2018. Immunity. 49(5):958-970 . PubMed
  22. Zhang T, et al. 2012. J Immunol. 189:2290. PubMed
  23. Narsale A, Moya R, Robertson H 2016. Data Brief. 8: 1348-51. PubMed
  24. Chen Y, et al. 2021. Transl Lung Cancer Res. 10:2193. PubMed
  25. Zhang J, et al. 2022. Nature. 609:369. PubMed
  26. Kashima Y, et al. 2022. Life Sci Alliance. 5:. PubMed
  27. Cai J, et al. 2021. eLife. 10:00. PubMed
  28. Liu J, et al. 2021. Medicine (Baltimore). 100:e24619. PubMed
  29. Kilpelainen A, et al. 2022. Front Immunol. 13:815041. PubMed
  30. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  31. Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed
  32. Du Q, et al. 2018. J Immunol. 201:533. PubMed
  33. Yang B, et al. 2015. Cell Immunol. Available online 12 August 2015. PubMed
  34. Gao X, et al. 2022. iScience. 25:104911. PubMed
  35. Leclercq G, et al. 2022. J Immunother Cancer. 10:. PubMed
  36. Bending D, et al. 2015. J Immunol. 195: 5616 - 5624. PubMed
  37. Verma K, et al. 2017. PLoS One.. 10.1371/journal.pone.0183828. PubMed
  38. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  39. Teni Nurlatifah HR, et al. 2021. Med Arch. 75:335. PubMed
  40. Tong L, et al. 2021. Front Microbiol. 12:704449. PubMed
  41. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  42. Yang YK, et al. 2021. Stem Cell Res Ther. 12:156. PubMed
  43. Barresi V, et al. 2020. J Clin Med. 9:00. PubMed
  44. Hr TN, et al. 2021. Allergol Immunopathol (Madr). 49:193. PubMed
  45. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  46. Loo Yau H, et al. 2021. STAR Protocols. 2(2):100549. PubMed
  47. Wang L, et al. 2018. Oncol Lett. 15:8635. PubMed
  48. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  49. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  50. Jiang J, et al. 2016. Sci Rep. 6: 32320. PubMed
  51. Hui Z, et al. 2022. Cell Death Dis. 13:607. PubMed
RRID
AB_571950 (BioLegend Cat. No. 317407)
AB_571950 (BioLegend Cat. No. 317408)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 4    Revision Date: 07.13.2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account